Get the Stockscreener App
14.45
5.24%
0.72
After Hours:
14.48
0.03
+0.21%
Mediwound Ltd stock is traded at $14.45, with a volume of 86,062.
It is up +5.24% in the last 24 hours and down -16.28% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$13.73
Open:
$13.73
24h Volume:
86,062
Relative Volume:
0.94
Market Cap:
$185.72M
Revenue:
$16.96M
Net Income/Loss:
$-23.88M
P/E Ratio:
-6.8908
EPS:
-2.097
Net Cash Flow:
$-20.66M
1W Performance:
-0.76%
1M Performance:
-16.28%
6M Performance:
-20.03%
1Y Performance:
-33.41%
1-Day Range:
$13.72
$14.48
1-Week Range:
$13.54
$15.00
52-Week Range:
$13.54
$22.09
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
14.45 | 176.46M | 16.96M | -23.88M | -20.66M | -2.097 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Insider Buying: Nachum Shamir Acquires 6,000 Shares of MediWound Ltd (MDWD) - GuruFocus
Director at MediWound (MDWD) buys 6,000 ordinary shares in market - Stock Titan
MediWound Ltd. Stock Plummets to New 52-Week Low of $13.58 - Markets Mojo
Insider Buying: David Fox Acquires Shares of MediWound Ltd (MDWD) - GuruFocus
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MediWound (MDWD) director buys 3,537 ordinary shares on open market - Stock Titan
MediWound Q1 earnings call highlights - MSN
Director Rubinstein buys MediWound (MDWD) shares and holds multiple options - Stock Titan
MDWD Stock Price, Quote & Chart | MEDIWOUND LTD (NASDAQ:MDWD) - ChartMill
MediWound Shares Slide This Week; BARDA Moves in Focus - Bez Kabli
MediWound Ltd. Hits New 52-Week Low at USD 14.14 - Markets Mojo
MediWound (MDWD) Slips 1.58% as Stock Holds Near Critical Support at $13.61Price Momentum Stocks - The Legal Advocate
MediWound (MDWD) Insider Trading Activity 2026 - MarketBeat
5 Stocks Better Than MediWound as Q1 Revenue Declines - HarianBasis.co
A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
MDWD Maintains Outperform by Oppenheimer -- Price Target Lowered to $32 - GuruFocus
MDWD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $36 - GuruFocus
Oppenheimer Adjusts MediWound Price Target to $32 From $33, Maintains Outperform Rating - Moomoo
Oppenheimer Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $32 - Moomoo
Will MediWound (NASDAQ:MDWD) Spend Its Cash Wisely? - Yahoo Finance
MediWound Ltd. (NASDAQ:MDWD) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36 - Moomoo
MediWound: Q1 Earnings Snapshot - AOL.com
MediWound Q1 2026 Earnings Call Transcript - MarketBeat
MediWound (MDWD) Q1 Loss Of US$0.23 Per Share Reinforces Bearish Profitability Narratives - simplywall.st
Q3 2025 Mediwound Ltd Earnings Call Transcript - GuruFocus
Q1 2026 Mediwound Ltd Earnings Call Transcript - GuruFocus
MediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue Challenges - GuruFocus
Oppenheimer lowers MediWound stock price target to $32 on revenue miss - Investing.com UK
Oppenheimer lowers MediWound stock price target to $32 on revenue miss By Investing.com - Investing.com Australia
MediWound Q1 2026 earnings preview - MSN
MediWound Q1 Earnings Call Highlights - sharewise.com
MediWound (MDWD) Reports Q1 Revenue Below Expectations - GuruFocus
MediWound Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Mediwound Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
MediWound Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MEDIWOUND ($MDWD) Releases Q1 2026 Earnings - Quiver Quantitative
MediWound Q1 2026 Results Highlight EscharEx Trial Progress and BARDA Boost for NexoBrid - TipRanks
MDWD: Q1 revenue fell but margin improved; EscharEx and NexoBrid progress support 2026 outlook - TradingView
MediWound (NASDAQ: MDWD) Q1 2026 revenue drops as 2026 guidance held - Stock Titan
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update - Caledonian Record
MediWound Ltd. Reaffirms Revenue Guidance for the Full-Year 2026 - marketscreener.com
MediWound (MDWD) Prepares for Q1 2026 Earnings Report - GuruFocus
MDWD Q4 2025 Earnings: Narrower Loss Beats Estimates as Operational Focus ContinuesProduct Revenue Analysis - The Legal Advocate
(MDWD) Risk Channels and Responsive Allocation - Stock Traders Daily
Mediwound Ltd expected to post a loss of 65 cents a shareEarnings Preview - TradingView
MediWound Ltd. (MDWD) Holds Near Support as Minor Decline Tests Key FloorShared Momentum Picks - Newser
MDWD PE Ratio & Valuation, Is MDWD Overvalued - Intellectia AI
MediWound Ltd. (MDWD) Presents at European Wound Management Association (EWMA) 2026Slideshow - Seeking Alpha
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):